Skip to main content
. 2022 Nov 2;11(1):2141011. doi: 10.1080/2162402X.2022.2141011

Figure 2.

Figure 2.

Tbc1d10c deficiency increases tumor-infiltrating CD8 effector cell levels. (A) Schematic of the experimental model for EGFP induction in chemically induced cutaneous SCCs in Tbc1d10c-CreERT2;R26mT/mG bigenic mice. (B) Representative micrograph showing EGFP labeling and immunofluorescence detection of Krt14+ SCC tumor cells in sections of chemically induced cutaneous SCCs from tamoxifen-treated bigenic mice. (C) Bar graph showing average flow cytometric detection of Tbc1d10c-expressing (EGFP+) immune lineages from nine bigenic cutaneous SCCs. Red boxes group the total pool of CD11b+ or CD8+ tumor-infiltrating cells. (D-I) Bar graphs showing the average percentages of total (D,F,H) and activated (E,G,I) CD8 + T cells from SCC (D-E; n = 4 tumors), B16 (F-G; n = 4 tumors) and MC38 (H-I; n = 6 tumors) xenografts. P values were determined by unpaired Student’s t-test. (J) Bar graph showing the fold-change differences in the CD8/CD4 Treg ratio for SCC and B16 tumors in Tbc1d10c−/− mice compared to wild-type (WT ratios set at graph baseline). Abbreviations: WT, Tbc1d10c+/+; KO, Tbc1d10c−/.